Prime Medicine, Inc. financial data

Symbol
PRME on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
60 First St., Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 557 % -30.6%
Debt-to-equity 43.9 % +169%
Return On Equity -115 % -72.2%
Return On Assets -79.9 % -39.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 131M shares +34.8%
Common Stock, Shares, Outstanding 131M shares +34.8%
Entity Public Float 603M USD
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 120M shares +30.4%
Weighted Average Number of Shares Outstanding, Diluted 120M shares +30.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 209K USD
Research and Development Expense 163M USD -1.53%
General and Administrative Expense 50.9M USD +27.6%
Operating Income (Loss) -226M USD -29%
Nonoperating Income (Expense) 7.04M USD +120%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -219M USD -27.6%
Earnings Per Share, Basic -2.06 USD/shares -194%
Earnings Per Share, Diluted -2.06 USD/shares -194%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 118M USD +168%
Cash, Cash Equivalents, and Short-term Investments 176M USD +6.17%
Other Assets, Current 9.54M USD
Assets, Current 246M USD +33.3%
Property, Plant and Equipment, Net 23.3M USD +5.7%
Operating Lease, Right-of-Use Asset 49.4M USD +186%
Other Assets, Noncurrent 0 USD -100%
Assets 333M USD +39.2%
Accounts Payable, Current 5.43M USD -61.6%
Employee-related Liabilities, Current 7.51M USD
Accrued Liabilities, Current 18.7M USD +33.2%
Contract with Customer, Liability, Current 9.28M USD
Liabilities, Current 37.9M USD -3.78%
Contract with Customer, Liability, Noncurrent 62.6M USD
Deferred Income Tax Liabilities, Net 134K USD +74%
Operating Lease, Liability, Noncurrent 36.8M USD +531%
Liabilities 143M USD +217%
Accumulated Other Comprehensive Income (Loss), Net of Tax 21K USD
Retained Earnings (Accumulated Deficit) -645M USD -51.5%
Stockholders' Equity Attributable to Parent 190M USD -2.3%
Liabilities and Equity 333M USD +39.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -67.7M USD -62.9%
Net Cash Provided by (Used in) Financing Activities 157M USD
Net Cash Provided by (Used in) Investing Activities -37M USD -192%
Common Stock, Shares Authorized 775M shares 0%
Common Stock, Shares, Issued 131M shares +34.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 52.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 132M USD +130%
Deferred Tax Assets, Valuation Allowance 119M USD +91.9%
Deferred Tax Assets, Gross 123M USD +74.3%
Operating Lease, Liability 41.2M USD +142%
Payments to Acquire Property, Plant, and Equipment 2.32M USD +16.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -219M USD -27.8%
Lessee, Operating Lease, Liability, to be Paid 208M USD +1042%
Property, Plant and Equipment, Gross 35.2M USD +24.4%
Operating Lease, Liability, Current 4.48M USD -60%
Lessee, Operating Lease, Liability, to be Paid, Year Two 23.4M USD +781%
Lessee, Operating Lease, Liability, to be Paid, Year One 19.8M USD +104%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +40.7%
Deferred Income Tax Expense (Benefit) 134K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 30.2M USD +2449%
Lessee, Operating Lease, Liability, to be Paid, Year Three 22.9M USD +1262%
Deferred Tax Assets, Operating Loss Carryforwards 36M USD +76.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 22.3M USD +3832%
Additional Paid in Capital 834M USD +34.6%
Depreciation, Depletion and Amortization 5.66M USD +32.3%
Share-based Payment Arrangement, Expense 24.6M USD +104%